[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Daewon Pharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":127},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,63,84,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100622364","phase-1-drug-drug-interaction-between-dw4421-and-amoxicillinclarithromycin-100622364",false,"NCT07382661","Drug-Drug Interaction Between DW4421 and Amoxicillin\u002FClarithromycin","A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetics Drug-drug Interaction of DW4421 and Amoxicillin\u002FClarithromycin in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Healthy adult aged 19 to 50 (inclusive) years, at the time of screening.\n* Subjects weighing between 50 kg and 90 kg with BMI between 18 and 27 kg\u002Fm2 (inclusive) at screening visit.\n\nExclusion Criteria:\n\n* Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history.",true,"ALL","19 Years","50 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","Drug-Drug Interaction between DW4421 and Amoxicillin\u002FClarithromycin",[28],"Healthy Adult Volunteers","NOT_YET_RECRUITING","2026-02-02",{"date":32,"type":33},"2026-02-04","ACTUAL",{"date":35,"type":22},"2026-02",{"date":37,"type":22},"2026-10",{"name":39,"class":40},"Daewon Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":41},"100620994","phase-1-a-phase-1-clinical-trial-to-evaluate-the-safety-and-pharmacokinetics-of-dw4421-t1-and-dw4421s-t1-in-healthy-adult-volunteers-100620994","NCT07364851","A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421-T1 and DW4421S-T1 in Healthy Adult Volunteers","A Randomized, Open-label, Single-dose, 2-sequence, Two-period, Crossover Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of DW4421-T1 and DW4421S-T1 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult aged 19 to 50 (inclusive) years\n* Subjects weighing between 50 kg and 90 kg with BMI between 18 and 27 kg\u002Fm2 (inclusive)\n\nExclusion Criteria:\n\n* clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history",{"count":50,"type":22},38,[25],"Safety and pharmacokinetic characteristics evaluation of DW4421-T1 and DW4421S-T1",[54],"Healthy Adult Volunteer","2026-01-18",{"date":57,"type":33},"2026-01-23",{"date":59,"type":22},"2026-03-06",{"date":61,"type":22},"2026-08-30",{"name":39,"class":40},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":23,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":41},"100619820","phase-1-evaluate-the-safety-tolerability-and-pharmacokinetics-of-dw5524-in-healthy-adult-volunteers-100619820","NCT07349589","Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers","A Randomized, Open-label, Single-dose, Parallel-design, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult volunteers aged 19 years or older at the time of screening\n* Individuals weighing 50.0 kg or more and having a body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening\n\nExclusion Criteria:\n\n* Those with a current or past medical history of clinically significant liver, kidney, nervous, mental, respiratory, endocrine, blood disease, tumor, genitourinary, cardiovascular, digestive, or musculoskeletal diseases.",{"count":71,"type":22},48,[25],"This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5524 in healthy adult volunteers.",[75],"Healthy Adult","2026-01-14",{"date":78,"type":33},"2026-01-20",{"date":80,"type":22},"2026-02-01",{"date":82,"type":22},"2026-12-01",{"name":39,"class":40},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":41},"100619332","phase-1-a-phase-1-clinical-trial-to-evaluate-the-safety-and-ddi-of-dw4421-and-3-nsaids-100619332","NCT07343245","A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs","A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics Drug-Drug Interaction of DW4421 and 3 NSAIDs in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult aged 19 to 50 (inclusive) years, at the time of screening.\n* Subjects weighing between 50 kg and 90 kg with BMI between 18 and 27 kg\u002Fm2 (inclusive) at screening visit.\n\nExclusion Criteria:\n\n* Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history",{"count":92,"type":22},150,[25],"Drug-Drug Interaction between DW4421 and three different kinds of NSAIDs",[75],"RECRUITING","2026-01-06",{"date":99,"type":33},"2026-01-15",{"date":101,"type":33},"2025-12-01",{"date":103,"type":22},"2026-06-17",{"name":39,"class":40},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":41},"100605895","phase-3-study-to-evaluate-the-efficacy-and-safety-of-dw1807-in-perennial-allergic-rhinitis-patients-with-asthma-100605895","NCT07168473","Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma","A Randomized, Double-blind, Active-controlled, Parallel, Multi-center, Phase 3 Trial to Compare and Evaluate the Efficacy and Safety of DW1807 and DW1807-R2 in Perennial Allergic Rhinitis Patients With Asthma","Inclusion Criteria:\n\n\\\u003CScreening Visit\\>\n\n1. Male or female adults aged 19 years or older.\n2. Individuals with a confirmed history or treatment record of perennial allergic rhinitis for at least 2 years at the time of screening.\n3. Individuals who have a positive result on an allergy skin prick test or serum allergen-specific IgE antibody test (e.g., MAST or ImmunoCAP) conducted within 1 year prior to screening, and have a documented history of allergy to at least one perennial allergen (e.g., house dust mites, cats, dogs, molds, etc.).\n4. Individuals diagnosed with asthma classified as Step 2 to Step 4.\n5. Individuals who voluntarily provide written informed consent to participate in this clinical trial.\n\n\\\u003CRandomization Visit\\>\n\n1. Subjects who meet all of the following criteria based on self-assessed nasal symptom scores recorded in the subject diary during the 7-day run-in period.\n\n   ① Performed nasal symptom evaluations twice daily (morning and evening) on at least 4 days during the run-in period.\n\n   ② Had an average daily Reflective Total Nasal Symptom Score (rTNSS) of ≥6 (maximum score: 12).\n2. Subjects with medication compliance of ≥80% during the 7-day run-in period.\n\nExclusion Criteria:\n\n\\\u003CA. Disease and Medical History-Related Exclusion Criteria\\>\n\n1. Individuals diagnosed with non-allergic rhinitis of other causes.\n2. Individuals with a documented acute exacerbation of asthma within 12 weeks prior to screening.\n3. Individuals diagnosed with pulmonary diseases other than asthma.\n4. Individuals diagnosed with the following types of sinusitis:\n\n   ① Acute sinusitis within 4 weeks prior to screening.\n\n   ② Clinically significant chronic sinusitis, as determined by the investigator.\n5. Individuals with nasal polyps or other clinically significant nasal structural abnormalities.\n6. Individuals who have undergone nasal or perinasal surgery within 12 weeks prior to screening.\n7. Individuals with a documented upper respiratory tract infection (including the common cold) or systemic infection within 3 weeks prior to screening.\n\n\\\u003CB. Concomitant Medication Use\\>\n\n1. Subjects who have initiated immunotherapy or changed the dosage within 4 weeks prior to the screening visit.\n2. Subjects who are on chronic use of medications that, in the opinion of the investigator, may interfere with the assessment of the investigational product's efficacy (e.g., tricyclic antidepressants).\n3. Subjects who are currently taking, or are expected to require during the study, any medications that are prohibited as per the protocol.\n\n\\\u003CC. Laboratory Criteria\\>\n\n1. Subjects with serum AST (GOT) or ALT (GPT) levels \\> 2 × the upper limit of normal (ULN) based on screening test results.\n2. Subjects with an estimated glomerular filtration rate (eGFR, calculated by CKD-EPI) \\\u003C 30 mL\u002Fmin\u002F1.73 m² based on screening test results.",{"count":113,"type":22},274,[115],"PHASE3","This study aims to compare the efficacy and safety of DW1807 and DW1807-R2 in patients with perennial allergic rhinitis and comorbid asthma. The primary objective is to demonstrate the superiority of DW1807 over DW1807-R2 in improving the reflective total nasal symptom score (rTNSS) after 4 weeks of treatment.",[118],"Perennial Allergic Rhinitis Accompanied by Asthma","2025-09-04",{"date":121,"type":33},"2025-09-11",{"date":123,"type":33},"2024-09-09",{"date":125,"type":22},"2026-09-18",{"name":39,"class":40},""]